Shah Rahimian, MD

Chief Medical Officer, North America

Dr. Rahimian has over two decades of direct senior level experience in clinical development and medicine.  He joins Virogin with extensive industry expertise and focus in immune-oncology and Intratumoral therapeutics.  He was most recently Senior Vice President of Clinical Development at Coherus Biosciences where he led the oncology drug development and collaborations.  He was previously Vice President of Clinical Development and medical lead of oncology at Idera Pharmaceuticals where he was responsible for advancing innovative and global oncology programs.  He held several other leadership positions at AstraZeneca, MedImmune, Targazyme, Antria and Illumina.  As a recognized leader in the biotechnology and pharmaceutical industry, his achievements include successful conduct of several early and late-stage clinical trials, submission of several BLAs and NDAs, drug approvals in the US and authoring of several publications in peer reviewed journals.

Dr. Rahimian earned his MD degree from the University of Istanbul where he also completed his training in general surgery, internal medicine and oncology.  He received subsequent training in oncology from the University of Pittsburgh, and in immunology from Harvard Medical School.